Jefferies raises Nanobiotix stock price target to EUR21.00 on broad cancer potential
PositiveFinancial Markets

Jefferies has raised its price target for Nanobiotix to EUR 21.00, highlighting the company's broad potential in cancer treatment. This adjustment reflects growing confidence in Nanobiotix's innovative approaches to oncology, which could significantly impact patient care and the market. Investors and stakeholders should take note, as this could signal a promising future for the company and its contributions to cancer therapies.
— Curated by the World Pulse Now AI Editorial System